Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Angel Cooper"'
Autor:
Robert Maroko, Mary Beth Sabol, Nathalie Castaing, Gary Dukart, Regöly-Mérei J, John M. Embil, Jean Yan, Zsófia Ozsvár, Laszlo Lauf, Nathalie Dartois, Ismael Mitha, Angel Cooper
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 78(4):469-480
A phase 3, randomized, double-blind trial was conducted in subjects with diabetic foot infections without osteomyelitis (primary study) or with osteomyelitis (substudy) to determine the efficacy and safety of parenteral (intravenous [iv]) tigecycline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e79a9ab47d7cdf58a1d782c7b7194835
Publikováno v:
The Open Respiratory Medicine Journal
Introduction: This study was conducted to evaluate the efficacy of tigecycline (TGC) versus levofloxacin (LEV) in hospitalized patients with community-acquired pneumonia (CAP) using pooled data and to perform exploratory analyses of risk factors asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103a558c172506b474a54dca4f196e78
http://europepmc.org/articles/PMC3601338
http://europepmc.org/articles/PMC3601338
Autor:
Jeffrey P. Hammel, Paul G. Ambrose, Joan M. Korth-Bradley, Christopher M. Rubino, C. Angel Cooper, Sujata M. Bhavnani, Nathalie Dartois, Alan Forrest
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:1065-1072
Pharmacokinetic and clinical data from tigecycline-treated patients with hospital-acquired pneumonia (HAP) who were enrolled in a phase 3 clinical trial were integrated in order to evaluate pharmacokinetic-pharmacodynamic (PK-PD) relationships for ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5707ea8bc68c0f75157bbdeeb071f0ff
https://doi.org/10.1128/aac.01615-10
https://doi.org/10.1128/aac.01615-10
Autor:
Alan Forrest, Nathalie Dartois, Christopher M. Rubino, Paul G. Ambrose, Angel Cooper, Joan M. Korth-Bradley, Sujata M. Bhavnani, Gary Dukart
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:130-136
Exposure-response analyses for efficacy and safety were performed for tigecycline-treated patients suffering from community-acquired pneumonia. Data were collected from two randomized, controlled clinical trials in which patients were administered a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::920924ad349809455d72e94b99ee3d3d
https://doi.org/10.1128/aac.00277-10
https://doi.org/10.1128/aac.00277-10
Autor:
Chia Ming Chang, B. Nagari, Angel Cooper, Vishwanath Pai, Nathalie Dartois, Sylvie Jouve, Sacchidanand Sarvajnamurthy Aradhya, Yin Ching Chuang
Publikováno v:
Journal of Microbiology, Immunology and Infection. 44(2):116-124
Background To compare the monotherapy of tigecycline with vancomycin-aztreonam in hospitalized patients from India and Taiwan with complicated skin and skin structure infections (cSSSIs). Methods Safety and efficacy data were analyzed for Indian ( n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9c70bdd0e32fb491bbabb2c741a9e7f
Autor:
Krasimir, Vasilev, Galina, Reshedko, Remus, Orasan, Miguel, Sanchez, Juri, Teras, Tim, Babinchak, Gary, Dukart, Angel, Cooper, Nathalie, Dartois, Hassan, Gandjini, Russ, Orrico, Evelyn, Ellis-Grosse, Silvestrs, Zebolds
Publikováno v:
Journal of Antimicrobial Chemotherapy. 62:i29-i40
Objectives To evaluate the efficacy and safety of tigecycline in patients with selected serious infections caused by resistant Gram-negative bacteria, or failures who had received prior antimicrobial therapy or were unable to tolerate other appropria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de5b3fee3c48efe12119c2c3c05239e
https://doi.org/10.1093/jac/dkn249
https://doi.org/10.1093/jac/dkn249
Autor:
Cristina, Tanaseanu, Carlos, Bergallo, Osvaldo, Teglia, Abel, Jasovich, Maria Eugenia, Oliva, Gary, Dukart, Nathalie, Dartois, C Angel, Cooper, Hassan, Gandjini, Rajiv, Mallick, Marius, Zolubas
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 61:329-338
Tigecycline (TGC), a glycylcycline, has expanded activity against Gram-positive and Gram-negative, anaerobic, and atypical bacteria. Two phase 3 studies were conducted. Hospitalized patients with community-acquired pneumonia (CAP) were randomized to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de4b69e126c64d87ddabe328d710a4d3
https://doi.org/10.1016/j.diagmicrobio.2008.04.009
https://doi.org/10.1016/j.diagmicrobio.2008.04.009
Autor:
Michael H. Metzler, Angel Cooper, Wedad Kassira, Mary C. McCarthy, Manjari Joshi, Stephen E. Olvey
Publikováno v:
Respiratory Medicine. 100:1554-1565
Summary This randomized, double-blind, multicenter study compared the efficacy and safety of piperacillin/tazobactam (P/T) and imipenem/cilastatin (IMP), both in combination with an aminoglycoside, in hospitalized patients with acute nosocomial pneum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002fc16a56112d49a5e5a5a5114f746c
https://doi.org/10.1016/j.rmed.2006.01.004
https://doi.org/10.1016/j.rmed.2006.01.004
Autor:
Alan Forrest, Christopher M. Rubino, Angel Cooper, Paul G. Ambrose, Joan M. Korth-Bradley, Sujata M. Bhavnani, Gary Dukart
Publikováno v:
Antimicrobial agents and chemotherapy. 54(12)
Tigecycline is a new-generation of tetracycline (glycylcyclines) and is active in vitro against bacteria that possess any of the classical genes that confer tetracycline resistance through ribosomal protection or efflux pumps. Herein, tigecycline dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba3ad5d24fb3fb27e5790dd82b3ee011
https://pubmed.ncbi.nlm.nih.gov/20921315
https://pubmed.ncbi.nlm.nih.gov/20921315
Autor:
Jianwei Bi, Dawei Liu, Yunsong Yu, Rong Li, Zhiyong Wu, Xiaochun Ma, Lunan Yan, Angel Cooper, Yingyuan Zhang, Xiaoping Chen, Xisheng Leng, Jufang Wu, Junming Wei, Zhiwei Quan, Zhangjing Chen, Robert Maroko
Publikováno v:
BMC Infectious Diseases, Vol 10, Iss 1, p 217 (2010)
BMC Infectious Diseases
BMC Infectious Diseases
Background Tigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and facultative Gram-pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aed36bcd2eec14896c5c8e7b0dacb39a
http://www.biomedcentral.com/1471-2334/10/217
http://www.biomedcentral.com/1471-2334/10/217